DK1809622T3 - Inhibitorer af interaktionen mellem MDM2 og P53 - Google Patents
Inhibitorer af interaktionen mellem MDM2 og P53Info
- Publication number
- DK1809622T3 DK1809622T3 DK05786991.9T DK05786991T DK1809622T3 DK 1809622 T3 DK1809622 T3 DK 1809622T3 DK 05786991 T DK05786991 T DK 05786991T DK 1809622 T3 DK1809622 T3 DK 1809622T3
- Authority
- DK
- Denmark
- Prior art keywords
- mdm2
- inhibitors
- interaction
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04077630 | 2004-09-22 | ||
US61390204P | 2004-09-28 | 2004-09-28 | |
PCT/EP2005/054604 WO2006032631A1 (en) | 2004-09-22 | 2005-09-16 | Inhibitors of the interaction between mdm2 and p53 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1809622T3 true DK1809622T3 (da) | 2010-11-08 |
Family
ID=34928531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05786991.9T DK1809622T3 (da) | 2004-09-22 | 2005-09-16 | Inhibitorer af interaktionen mellem MDM2 og P53 |
Country Status (30)
Country | Link |
---|---|
US (2) | US7834016B2 (da) |
EP (1) | EP1809622B1 (da) |
JP (1) | JP5156378B2 (da) |
KR (1) | KR101331786B1 (da) |
CN (1) | CN101023074B (da) |
AP (1) | AP2446A (da) |
AR (1) | AR053412A1 (da) |
AT (1) | ATE474833T1 (da) |
AU (1) | AU2005286525B2 (da) |
BR (1) | BRPI0515594B8 (da) |
CA (1) | CA2579915C (da) |
CR (1) | CR9081A (da) |
DE (1) | DE602005022472D1 (da) |
DK (1) | DK1809622T3 (da) |
EA (1) | EA012452B1 (da) |
EC (1) | ECSP077335A (da) |
ES (1) | ES2349358T3 (da) |
HK (1) | HK1107651A1 (da) |
HR (1) | HRP20100561T1 (da) |
IL (1) | IL182009A (da) |
MX (1) | MX2007003375A (da) |
MY (1) | MY136800A (da) |
NO (1) | NO341281B1 (da) |
NZ (1) | NZ553646A (da) |
SG (1) | SG155941A1 (da) |
SI (1) | SI1809622T1 (da) |
TW (1) | TWI372758B (da) |
UA (1) | UA91027C2 (da) |
WO (1) | WO2006032631A1 (da) |
ZA (1) | ZA200702341B (da) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007014114A (es) | 2005-05-10 | 2008-03-14 | Intermune Inc | Derivados de piridona para modular el sistema de proteina cinasa activada por estres. |
US8921376B2 (en) * | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
EP1999126B1 (en) * | 2006-03-22 | 2010-06-09 | Janssen Pharmaceutica, N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
CA2644643C (en) * | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
CN101466676B (zh) * | 2006-04-12 | 2012-07-18 | 默沙东公司 | 吡啶基酰胺类t-型钙通道拮抗剂 |
MX2009000148A (es) | 2006-07-07 | 2009-10-26 | Kalypsys Inc | Inhibidores heteroaril biciclicos de fosfodiesterasa 4. |
US8138205B2 (en) | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
WO2008121442A2 (en) * | 2007-02-09 | 2008-10-09 | The Uab Research Foundation | Pa28-gamma regulation in cells |
US20100129933A1 (en) * | 2007-04-26 | 2010-05-27 | Forschungszentrum Karlsruhe Gmbh | Method for detecting the binding between mdm2 and the proteasome |
PA8792401A1 (es) | 2007-08-06 | 2009-03-31 | Janssen Pharmaceutica Nv | Fenilendiaminas |
JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
ES2382701T3 (es) * | 2007-09-21 | 2012-06-12 | Janssen Pharmaceutica, N.V. | Inhibidores de la interacción entre MDM2 y p53 |
US8637513B2 (en) * | 2007-10-24 | 2014-01-28 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide T-type calcium channel antagonists |
US8268777B2 (en) * | 2007-12-05 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
EP2224920A4 (en) * | 2007-12-06 | 2012-05-09 | Enanta Pharm Inc | PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS |
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
AR075235A1 (es) | 2009-02-04 | 2011-03-16 | Janssen Pharmaceutica Nv | Derivados de indol como agentes anticancer. |
WO2010107485A1 (en) * | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
KR20120124428A (ko) | 2009-12-30 | 2012-11-13 | 아르퀼 인코포레이티드 | 치환된 피롤로-아미노피리미딘 화합물 |
EP2588456A1 (en) * | 2010-07-02 | 2013-05-08 | Syngenta Participations AG | Novel microbiocidal dioxime ether derivatives |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
WO2012065022A2 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
KR101688268B1 (ko) | 2011-05-11 | 2016-12-20 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 스피로-옥신돌 mdm2 길항물질 |
US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
RU2509808C1 (ru) * | 2012-10-30 | 2014-03-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53 |
KR20140059002A (ko) * | 2012-11-07 | 2014-05-15 | 한국과학기술원 | 다제내성 종양 치료를 위한 항암제 및 치료방법 |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
SI3102576T1 (sl) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals, Llc | Inhibitorji dihidropirolopiridina ROR-gama |
JP6525437B2 (ja) | 2014-04-02 | 2019-06-05 | インターミューン, インコーポレイテッド | 抗線維性ピリジノン |
WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
CA2976752C (en) | 2015-02-20 | 2019-12-17 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
PE20180327A1 (es) * | 2015-05-11 | 2018-02-13 | Basf Se | Proceso para preparar 4-amino-piridazinas |
BR122019027518B8 (pt) * | 2015-05-11 | 2021-04-13 | Basf Se | processos para a preparação de um composto, composto de amina de dicloropiridazina e mistura do composto de amina de dicloropiridazina |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
EP3331895B1 (en) | 2015-08-06 | 2020-07-29 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
RU2021102253A (ru) | 2016-04-06 | 2021-03-03 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка mdm2 |
CA3020281A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2018039310A1 (en) | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
IL298639A (en) | 2017-07-24 | 2023-01-01 | Vitae Pharmaceuticals Llc | Inhibitors of gamma ror |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
CN108409839B (zh) * | 2018-02-13 | 2020-08-11 | 中国人民解放军军事科学院军事医学研究院 | 一种MDM2与p53相互作用的多肽抑制剂及其应用 |
CN111757731B (zh) | 2018-02-20 | 2024-06-25 | 法国施维雅药厂 | 三取代苯并三唑衍生物的使用方法 |
IL295374A (en) | 2020-02-04 | 2022-10-01 | Mindset Pharma Inc | 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders |
TR202002325A2 (tr) * | 2020-02-17 | 2021-08-23 | Bahcesehir Ueniversitesi | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4 |
CN113293046B (zh) * | 2021-05-26 | 2021-11-30 | 安徽博洋润滑科技有限公司 | 一种低发尘润滑脂及其制备方法 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
AUPO863197A0 (en) | 1997-08-18 | 1997-09-11 | Fujisawa Pharmaceutical Co., Ltd. | Novel derivatives |
US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
US6309492B1 (en) | 1998-09-16 | 2001-10-30 | Marc A. Seidner | Polymer fill coating for laminate or composite wood products and method of making same |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
AU775123B2 (en) * | 1999-03-24 | 2004-07-15 | Anormed Inc. | Chemokine recpetor binding heterocyclic compounds |
AU1734401A (en) * | 1999-12-09 | 2001-06-18 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
CN1237061C (zh) | 2000-09-15 | 2006-01-18 | 阿诺麦德股份有限公司 | 结合趋化因子受体的杂环化合物 |
ATE372768T1 (de) | 2001-03-29 | 2007-09-15 | Lilly Co Eli | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste |
AU2002357728A1 (en) * | 2001-11-09 | 2003-05-19 | The Regents Of The University Of California | Alpha-helix mimicry by a class of organic molecules |
RU2004118243A (ru) | 2001-11-13 | 2006-01-10 | 3-Дименшенл Фамэсьютикэлс, Инк. (US) | Замещенные 1,4-бензодиазепины и их использование для лечения онкологических заболеваний |
RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
GB0428187D0 (en) | 2004-12-23 | 2005-01-26 | Univ Liverpool | Cancer treatment |
ES2345997T3 (es) * | 2005-01-14 | 2010-10-07 | Janssen Pharmaceutica Nv | Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular. |
EP2314297A1 (en) | 2006-04-05 | 2011-04-27 | Novartis AG | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
-
2005
- 2005-09-16 EP EP05786991A patent/EP1809622B1/en active Active
- 2005-09-16 ES ES05786991T patent/ES2349358T3/es active Active
- 2005-09-16 AT AT05786991T patent/ATE474833T1/de not_active IP Right Cessation
- 2005-09-16 NZ NZ553646A patent/NZ553646A/en not_active IP Right Cessation
- 2005-09-16 KR KR1020077008663A patent/KR101331786B1/ko active IP Right Grant
- 2005-09-16 SG SG200906267-0A patent/SG155941A1/en unknown
- 2005-09-16 CA CA2579915A patent/CA2579915C/en not_active Expired - Fee Related
- 2005-09-16 CN CN2005800317557A patent/CN101023074B/zh not_active Expired - Fee Related
- 2005-09-16 WO PCT/EP2005/054604 patent/WO2006032631A1/en active Application Filing
- 2005-09-16 DK DK05786991.9T patent/DK1809622T3/da active
- 2005-09-16 AU AU2005286525A patent/AU2005286525B2/en not_active Ceased
- 2005-09-16 MX MX2007003375A patent/MX2007003375A/es active IP Right Grant
- 2005-09-16 SI SI200531127T patent/SI1809622T1/sl unknown
- 2005-09-16 UA UAA200702657A patent/UA91027C2/ru unknown
- 2005-09-16 AP AP2007003947A patent/AP2446A/xx active
- 2005-09-16 JP JP2007532886A patent/JP5156378B2/ja not_active Expired - Fee Related
- 2005-09-16 US US11/575,552 patent/US7834016B2/en not_active Expired - Fee Related
- 2005-09-16 BR BRPI0515594A patent/BRPI0515594B8/pt not_active IP Right Cessation
- 2005-09-16 DE DE602005022472T patent/DE602005022472D1/de active Active
- 2005-09-16 EA EA200700699A patent/EA012452B1/ru not_active IP Right Cessation
- 2005-09-21 AR ARP050103960A patent/AR053412A1/es not_active Application Discontinuation
- 2005-09-21 TW TW094132574A patent/TWI372758B/zh not_active IP Right Cessation
- 2005-09-22 MY MYPI20054466A patent/MY136800A/en unknown
-
2007
- 2007-03-19 IL IL182009A patent/IL182009A/en active IP Right Grant
- 2007-03-20 ZA ZA200702341A patent/ZA200702341B/xx unknown
- 2007-03-22 EC EC2007007335A patent/ECSP077335A/es unknown
- 2007-04-20 CR CR9081A patent/CR9081A/es not_active Application Discontinuation
- 2007-04-23 NO NO20072058A patent/NO341281B1/no not_active IP Right Cessation
- 2007-12-04 HK HK07113244.0A patent/HK1107651A1/xx not_active IP Right Cessation
-
2010
- 2010-10-14 HR HR20100561T patent/HRP20100561T1/hr unknown
- 2010-11-03 US US12/938,633 patent/US8404683B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1809622T3 (da) | Inhibitorer af interaktionen mellem MDM2 og P53 | |
NO2017017I1 (no) | umeklinidium og vilanterol | |
DK2203440T3 (da) | Inhibitorer af interaktionen mellem MDM2 og P53 | |
DK1780295T3 (da) | Svejseforbindelse og svejsemateriale deraf | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
DK1771446T3 (da) | Azaindolinhibitorer af MTP og APOB | |
DK1592686T3 (da) | Gyrase-inhibitorer og anvendelser deraf | |
NO20081604L (no) | Nitrogeninneholdende heterocyklisk forbindelse og farmasøytisk anvendelse derav | |
DK1732892T3 (da) | Tetrahydrocarbazoler og derivater | |
DK1937664T3 (da) | Hydrazidforbindelse og pesticid anvendelse af den samme | |
DE602005012267D1 (de) | N von geräten | |
ATE455629T1 (de) | Rasierer und kassetten | |
ATE542648T1 (de) | Rasierer und kassetten | |
DK1713503T3 (da) | Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde | |
DK2072051T3 (da) | Kombination af azelastin og mometason | |
DK3321359T3 (da) | Variante former af uratoxidase og anvendelse deraf | |
NO20054709L (no) | Sammenfoyningssystem og anvendelse av dette | |
DK1814977T3 (da) | Arthrospira-baserede sammensætninger og anvendelser deraf | |
DE602005007987D1 (de) | achtelung und -entschachtelung | |
NO2016020I1 (no) | Imidacloprid og Flumetrin | |
DK1829874T3 (da) | Tricyklisk forbindelse og anvendelse deraf | |
ATE423117T1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone | |
DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
IS8145A (is) | Bý bíóísósterur af aktínóníni | |
DK1620058T3 (da) | Sammensætning til forbedring af kognition og hukommelse |